DeepModeling and Lepu Biopharma Achieve Key Milestone in Collaboration: Accelerating ADC Drug Innovation Through Advanced Computational Approaches

Recently, Lepu Biopharma Co., Ltd. ("LEPU BIOPHARMA") and DP Technology announced the achievement of a significant milestone in their ADC drug collaboration. This partnership has deeply integrated DP Technology’s ADC Linker-Payload design platform with LEPU BIOPHARMA’s ADC technology development platform, leveraging each other's strengths. Through multiple rounds of Linker iterative design and validation, the collaboration has optimized the overall drugability of ADCs within a relatively short period. Recently, this project achieved a key milestone, further validating the pathway of accelerating ADC innovative drug R&D through computational design. Moving forward, both parties will continue to deepen their R&D cooperation in this field, jointly committing to advancing and optimizing the process of innovative drug development.

The ADC Linker-Payload Design Platform, meticulously developed by DP Technology, is built upon the "RiDYMO® Difficult-to-Drug Target R&D Platform" and further integrates "an AI + First Principles-based computational approach for predicting linker cleavage sites." This ensures not only the precise release of the designed payload but also achieves excellent cell-killing effects and a "bystander" effect. Meanwhile, the designed antibody-drug conjugates (ADCs) exhibit superior hydrophilicity and plasma stability while maintaining high drug efficacy. Supported by LEPU BIOPHARMA’s mature and comprehensive ADC development system, the new ADC platform has demonstrated significant superiority in CDX efficacy experiments targeting multiple antigens. This project has been effectively validated in animal models, and candidate molecules are currently being developed for clinical-stage advancement.

LEPU BIOPHARMA Vice President and LEPU CY General Manager Lei FangExpressed high appreciation for this collaboration: "Introducing advanced computational methods to solve scientific problems and jointly pioneering breakthrough explorations are the common goals we strive for in this ADC project collaboration. As a leader in the AI for Science paradigm, DP Technology's newly developed ADC design platform has played a crucial role in this project. Combining LEPU BIOPHARMA’s mature ADC development system with AI-driven innovative ADC design not only brings new inspiration and ideas to ADC development but also significantly accelerates the ADC development process. Complementing each other's strengths, we jointly provide new inspiration and approaches for innovative ADC drug design."

CEO of DP Technology, Sun WeijieExpressed more expectations for future cooperation: "As an innovative biopharmaceutical company focused on cancer treatment, particularly in the fields of targeted therapy and immunotherapy, LEPU BIOPHARMA has deep experience and long-term accumulation in the development of innovative ADC drugs. We firmly believe that the close cooperation between the two parties will significantly accelerate the design and development of ADC drugs, with the potential to develop innovative, highly efficient, and differentiated ADC new drugs. I am full of expectations for the continuous and in-depth cooperation between the two parties in the field of pharmaceutical innovation!"

Currently, in response to various needs from industry partners in the ADC field, the DP Technology platform has successfully empowered multiple scenarios and projects. Examples include using AI + first-principles calculations to predict Linker cleavage sites and enhance attachment stability; leveraging pre-trained models combined with fine-tuning strategies, along with expert experience, to predict and modify Payload efflux, bystander killing, and other physicochemical properties; and continuously exploring and collaborating on the evaluation of overall ADC properties such as aggregation effects.

LEPULepu Biopharma Co., Ltd. is an innovative biopharmaceutical company based in China and focused globally on the field of cancer treatment, particularly targeted therapies and immunotherapies. The company is committed to developing innovative Antibody-Drug Conjugates (ADCs) through its advanced ADC technology platform, with the aim of creating more optimized and innovative drugs to better address the unmet clinical needs of cancer patients. Lepu Biopharma continues to develop a differentiated pipeline by combining internal research and development with strategic collaborations, while enhancing its in-house production capabilities. In China, the company leverages a professional sales and marketing team, and internationally, it advances the commercialization of its pipeline products through partnerships. Lepu Biopharma possesses end-to-end capabilities spanning key aspects of the biopharmaceutical value chain, including drug discovery, clinical development, CMC, and GMP-compliant manufacturing, and has established a dedicated sales and marketing team.